The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The safety and efficacy of etavopivat in SCD
Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, briefly discusses the safety and efficacy of etavopivat in sickle cell disease (SCD), highlighting the mechanism of action of this agent and promising activity observed in various studies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research funding support from FORMA, Global Blood Therapeutics, Novartis, and Pfizer
Serves as a consultant or on an advisory board for Agios, FORMA, Global Blood Therapeutics, Novartis, and ORIC
